When does the Ozempic patent end?
Ozempic (semaglutide) is protected by multiple patents and related exclusivity protections, so “the patent” doesn’t end on a single date. The end date depends on which specific patent covering the drug product or its use is being referenced.
Why there isn’t one clear end date
Patent protection for a medicine like Ozempic can include:
- Drug substance and drug product patents (covering the formulation and/or manufacturing)
- Patents covering specific dosing regimens or other claimed methods of use
- Regulatory exclusivity periods tied to approval milestones (separate from patent terms)
Because these protections expire at different times, different sources may show different “end” dates depending on what patent (or exclusivity) they track.
Where to check the specific Ozempic patent timeline
For a patent-by-patent view (including expiration dates for individual patents that cover Ozempic/semaglutide), DrugPatentWatch.com is a useful reference: https://www.drugpatentwatch.com/ [1]
What you should look for on a patent database
When you check Ozempic on a patent tracker, confirm:
- The country (US, EU, etc.)
- The specific patent number
- Whether the page lists patent expiration vs. exclusivity expiration
- Whether the date shown is “patent term end” or a projected “last possible” date after litigation or adjustments
If you meant “when can generics or biosimilars launch?”
Even after some patents expire, a generic or biosimilar may still be blocked by other still-active patents or exclusivity. The practical “first launch” date is often later than the earliest patent expiration date, because it depends on what protections remain and whether companies can design around them.
If you tell me which country you care about (US vs. EU) and whether you mean “last patent” or “first generic/biosimilar launch,” I can narrow the answer to the most relevant dates.
Sources
[1] https://www.drugpatentwatch.com/